HEAL Initiative: JCOIN Phase II Clinical Research Hubs (UM1 Clinical Trial Required)
ID: 354741Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $5M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354741

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-025.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity under the HEAL Initiative for the JCOIN Phase II Clinical Research Hubs, aimed at addressing substance use disorder (SUD) and overdose risks within the criminal-legal system. This initiative seeks applications for multi-site clinical trials that evaluate strategies to improve treatment engagement, retention, and health outcomes for justice-involved individuals, particularly focusing on the delivery of medication for opioid use disorder (MOUD) in jails and community settings. The funding, which can reach up to $5 million over five years, is intended to foster collaboration among justice and behavioral health providers, with a requirement for a Plan for Enhancing Diverse Perspectives to ensure inclusivity in research. Interested applicants must submit their proposals by January 22, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-025-Full-Announcement.html
    RFA-DA-25-025.html
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is launching the HEAL Initiative: JCOIN Phase II Clinical Research Hubs funding opportunity. This initiative focuses on addressing substance use disorder (SUD) and overdose risks within the criminal-legal system and community-based healthcare settings. The JCOIN aims to improve the delivery of effective interventions across key stages such as law enforcement, courts, jails, and re-entry services. The funding opportunity encourages applications for multi-site clinical trials to evaluate strategies that enhance treatment engagement, retention, and health outcomes for justice-involved individuals. Key dates include an application due date of January 23, 2025, with funding available up to $5 million over five years. Applicants must collaborate with justice and behavioral health providers and address issues like mental health comorbidities and polysubstance use. A Plan for Enhancing Diverse Perspectives is required to ensure inclusivity in research. The center's structure will involve several resource and support centers aimed at fostering collaboration and innovation in SUD treatment for diverse populations. This call reflects a critical response to the ongoing opioid crisis and aims to develop sustainable, evidence-based treatment models within the justice system.
    Similar Opportunities
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-25-078), aimed at supporting research that transforms addiction treatment and care to combat the ongoing overdose crisis. This initiative encourages phased applications (R61/R33), where the R61 phase focuses on exploratory activities without the need for existing pilot data, while the R33 phase seeks to implement larger studies based on successful R61 milestones, emphasizing stigma-free and patient-centered approaches. With up to $10 million allocated for FY2026 and a maximum award period of six years, applicants must include a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity, and applications are to be submitted through Grants.gov by the closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-23-054), aimed at supporting innovative research that bridges the gap between research findings and practical applications to combat the opioid overdose crisis. This initiative emphasizes the need for stigma-free, patient-centered care systems and focuses on understudied areas related to overdose prevention, requiring applicants to present preliminary data for significant projects within a maximum project period of five years and a budget of up to $750,000 in direct costs annually. The funding reflects a commitment to addressing health disparities and promoting effective addiction treatment and recovery solutions, with applications evaluated based on significance, innovation, feasibility, and stakeholder engagement. Interested applicants should note that the application deadline is March 20, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative funding opportunity titled "Translating Research to Practice to End the Overdose Crisis" (RFA-DA-23-053). This initiative aims to support research that translates findings into actionable practices to combat the ongoing overdose crisis in the U.S., with a focus on developing innovative, scalable, and equitable strategies for patient-centered care in addiction treatment. The funding mechanism allows for projects to span up to six years, divided into a two-year planning phase (R61) and a five-year implementation phase (R33), with an anticipated total funding of up to $15 million based on the quality of applications received. Interested applicants can find more details and submission guidelines at the provided link and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. The application deadline is March 20, 2025.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity for the development of medications aimed at preventing and treating substance use disorders (SUDs) and overdose. This initiative is structured into two phases: the UG3 phase focuses on achieving specific milestones within a two-year period, while the UH3 phase extends support for an additional three years for projects that successfully meet the UG3 milestones. Given the urgent need for effective treatments in light of rising overdose deaths, particularly from synthetic opioids and stimulants, this funding opportunity emphasizes innovative research methodologies and the effective application of existing medications. Interested applicants can seek funding of up to $3 million annually for a maximum of five years, with applications due by August 11, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-329.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the HEAL Initiative aimed at enhancing the implementation of preventive services for substance use disorders, specifically focusing on opioid misuse. This initiative invites applications for research that addresses gaps in the dissemination and implementation of prevention services, with a phased R61/R33 award mechanism allowing for up to six years of support, contingent on the successful completion of preliminary milestones. The overarching goal is to establish a sustainable prevention infrastructure that effectively reduces risks associated with substance use, emphasizing equity and community involvement in the research process. Interested applicants can find more information and apply by the deadline of January 16, 2026, with a projected funding amount of $4.65 million for the 2024 fiscal year. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-066.html.
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity under the HEAL Initiative, aimed at enhancing the implementation and sustainability of substance use preventive services. This initiative seeks to address the critical gaps between effective prevention research and its practical application, particularly in combating the opioid crisis, by soliciting applications for projects that demonstrate preliminary data and focus on strengthening prevention infrastructure. With approximately $4.65 million available for funding, grants can support projects for up to five years, with annual budget requests advised to remain under $800,000. Interested applicants must submit their proposals by January 16, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01), aimed at supporting early career researchers in developing expertise in implementation science related to substance use treatment and prevention. Applicants are required to conduct an independent clinical trial that applies implementation science to one of the four priority domains of the HHS Overdose Prevention Strategy, which includes prevention, treatment, harm reduction, and recovery support services. This initiative is crucial in addressing the ongoing overdose crisis by promoting the integration of evidence-based practices into routine care, fostering a diverse research community, and ensuring equitable access to effective treatment resources. The funding amount is approximately $1.1 million for FY2023, with awards anticipated for 3-5 years of research, and applications are due by November 12, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.